logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
arrow
Return

THRIVE

delete2026-06-01
delete0
PRE
AI
M
Michael T. Yen *
K
Kimberly Cockerham
P
Peerooz Saeed
S
Steven Leibowitz
R
Raghu C. Mudumbai
M
Michael Schittkowski
V
Vickie Lee
J
Jody Abrams
R
Roger E. Turbin
J
Julián Bermúdez Pío-Rendón
E
Eckart Bertelmann
E
Edwina Eade
N
Navdeep Nijhawan
M
Marta Pérez‐López
M
Marco Sales-Sanz
S
Sandy Zhang-Nunes
A
Andrea L. Kossler
A
Ashley Pajak
A
Abhijit Narvekar
R
Radhika Tripuraneni
DOI：10.1016/j.ophtha.2026.04.022delete
deleteOriginal
deleteShare
deleteSave
Abstract

Abstract

En 中文
Thyroid eye disease (TED) is a debilitating autoimmune disease with significant unmet needs. This study’s objective was to assess the efficacy and safety of veligrotug, a full antagonist monoclonal antibody to the insulin-like growth factor-1 receptor, in patients with active TED.

Journal

Ophthalmology cover
Ophthalmology
IF:
9.5
Papers:
1.3W
Citations:
5.0W

Organization

No organization information available
Cited Papers

Cited Papers

No cited papers available